Intro -- Contents -- Preface -- Section I. Professional Practice Considerations -- Chapter 1. Professional Practice Considerations -- A. Scope and standards -- B. Professional education -- C. Policies and procedures -- D. Antineoplastic medication safety -- E. Quality and safety monitoring -- References -- Chapter 2. Ethical and Legal Issues -- A. Ethical issues -- B. Legal issues related to cancer therapy -- References -- Chapter 3. Patient Education -- A. Patient education overview -- B. Short-term outcomes of patient education -- C. Long-term outcomes of patient education -- D. Barriers to patient education -- E. Methods of patient education -- F. Scope of information -- G. Documentation -- References -- Section II. Cancer and Cancer Treatment -- Chapter 4. Overview of Cancer and Cancer Treatment -- A. Definition of cancer -- B. The Cancer Care Continuum framework -- C. Cancer staging and grading -- D. Cancer treatment modalities -- E. Treatment approaches -- F. Treatment strategies -- G. Measuring response -- H. Factors affecting treatment response -- I. Adherence -- J. Toxicity grading and documentation -- References -- Chapter 5. Clinical Trials and Drug Development -- A. Clinical research -- B. Drug and biologic development process -- C. Expanded access -- References -- Section III. Cancer Therapeutics -- Chapter 6. Chemotherapy -- A. Chemotherapy in the treatment of cancer -- B. Classification of chemotherapy agents -- C. Chemotherapy classifications -- D. Combination chemotherapy principles -- References -- Chapter 7. Hormone Therapy -- A. Hormone therapy in the treatment of cancer -- B. Cancers treated with hormone therapy -- C. Hormone treatment categories -- References -- Chapter 8. Targeted Therapy -- A. Targeted therapies in the treatment of cancer -- B. Adverse effects of targeted therapies -- C. Drug-drug interactions.

References -- Chapter 9. Principles of the Immune System -- A. Overview of immunology -- B. Types of immune response -- C. Organs of the immune system -- D. Cells of the immune system -- E. Immune system proteins and receptors -- F. Phases of immune response -- G. Tumor escape mechanisms -- References -- Chapter 10. Immunotherapy -- A. Overview -- B. Modalities of immunotherapy -- C. General patient and family education -- References -- Section IV. Treatment Administration and Safety -- Chapter 11. Administration Considerations -- A. Components of safe and effective administration of cancer therapies -- B. Pretreatment -- C. Chemotherapy, targeted therapy, and immunotherapy dosing -- D. Verification -- E. Routes of chemotherapy, immunotherapy, and targeted therapy administration -- References -- Chapter 12. Safe Handling of Hazardous Drugs -- A. Safe handling and disposal of hazardous drugs -- B. Definition -- C. Antineoplastic drugs -- D. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings -- E. NIOSH List of Hazardous Drugs in Healthcare Settings -- F. Immunotherapy -- G. Routes of occupational exposure -- H. Hierarchy of hazard controls -- I. Guidelines for PPE -- J. Storage and labeling -- K. Safe handling precautions during compounding -- L. Transporting HDs -- M. Safe handling precautions during administration -- N. Special precautions for radiopharmaceuticals -- O. Handling body fluids -- P. Handling patient linens -- Q. Disposal of HDs and materials contaminated with HDs -- R. Procedures following acute HD exposure -- S. Spill management -- T. Requirements for policies regarding the handling of HDs -- References -- Chapter 13. Infusion-Related Complications -- A. Complications during or shortly after parenteral administration of cancer treatment -- B. Extravasation of vesicants resulting in potential tissue damage.

C. Irritation -- D. Flare reaction -- E. Acute infusion-related reactions -- F. Patient and caregiver education -- References -- Section V. Treatment-Related Complications -- Chapter 14. Myelosuppression -- A. Overview -- B. Types of cytopenias -- References -- Chapter 15. Gastrointestinal and Mucosal Toxicities -- A. Nausea and vomiting -- B. Anorexia and cachexia -- C. Diarrhea -- D. Colitis -- E. Pancreatitis -- F. Mucositis -- G. Perirectal cellulitis -- H. Constipation -- References -- Chapter 16. Cardiovascular Toxicities -- A. Overview -- B. Conduction pathway disorders -- C. Vascular abnormalities: hypertension -- D. Venous thromboembolism -- E. Coronary artery disease -- F. Left ventricular dysfunction and heart failure -- G. Myocarditis -- References -- Chapter 17. Pulmonary Toxicities -- A. Overview -- B. ILD -- C. Diffuse alveolar hemorrhage -- D. Acute promyelocytic leukemia treatment-related differentiation syndrome -- E. Pleural effusions -- F. Patient and family education -- References -- Chapter 18. Hepatic Toxicities -- A. Overview -- B. Pathophysiology -- C. Incidence -- D. Risk factors -- E. Clinical manifestations -- F. Pathologic manifestations associated with drug toxicity -- G. Assessment -- H. Collaborative management -- I. Patient and family education -- References -- Chapter 19. Genitourinary Toxicities -- A. Overview -- B. Antineoplastic-associated genitourinary toxicities -- C. Drug-specific considerations -- References -- Chapter 20. Altered Sexual and Reproductive Functioning -- A. Alterations in sexual functioning -- B. Alterations in reproductive functioning -- References -- Chapter 21. Cutaneous Toxicities and Alopecia -- A. Cutaneous toxicity -- B. Alopecia -- References -- Chapter 22. Endocrine Toxicities -- A. Overview -- B. Drug-specific endocrinopathies -- C. Immune checkpoint inhibitor-related endocrinopathies.

References -- Chapter 23. Fatigue -- A. Overview -- B. Pathophysiology -- C. Incidence -- D. Assessment -- E. Collaborative management -- F. Principles of patient and family education and care planning -- References -- Chapter 24. Neurologic Toxicities -- A. Overview -- B. Radiation-induced CNS toxicity -- C. Radiation-induced peripheral nervous system toxicity -- D. Chemotherapy-induced CNS toxicity -- E. Peripheral neuropathy -- F. Common antineoplastics conferring increased neurotoxicity -- G. Risk factors and prophylaxis -- H. Cognitive impairment -- I. Patient and family education -- References -- Chapter 25. Ocular Toxicities -- A. Overview -- B. Pathophysiology -- C. Incidence -- D. Risk factors -- E. Clinical manifestations -- F. Assessment -- G. Collaborative management -- H. Patient and family education -- References -- Section VI. Post-Treatment -- Chapter 26. Post-Treatment and Survivorship Care -- A. Overview -- B. Cancer survivorship care -- C. Long-term and late effects of cancer treatment -- References -- Appendices -- Appendix A. Clinical Practicum Evaluation: Part I -- Appendix B. Clinical Practicum Evaluation: Part II -- Appendix C. Sample Chemotherapy Order Template -- Appendix D. Antineoplastic Treatment Safety Checklist -- Appendix E. Consent for Antineoplastic Drug Treatment -- Appendix F. Distress Thermometer -- Appendix G. Hazardous Drug Administration Safe Handling Checklist -- Appendix H. Extravasation -- Appendix I. Vesicant Drug Extravasation Record -- Index.